 Todd Bull
Concepts (334)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 45 | 2024 | 1924 | 3.850 |
Why?
| | Scleroderma, Systemic | 6 | 2019 | 122 | 1.650 |
Why?
| | Pulmonary Embolism | 5 | 2022 | 235 | 1.220 |
Why?
| | Ventricular Dysfunction, Right | 7 | 2023 | 239 | 1.200 |
Why?
| | Vena Cava Filters | 2 | 2020 | 64 | 0.780 |
Why?
| | Epoprostenol | 5 | 2024 | 136 | 0.740 |
Why?
| | Thrombolytic Therapy | 3 | 2021 | 149 | 0.730 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2021 | 73 | 0.670 |
Why?
| | Airway Obstruction | 1 | 2021 | 164 | 0.630 |
Why?
| | Antihypertensive Agents | 3 | 2024 | 505 | 0.620 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 3 | 2024 | 1045 | 0.610 |
Why?
| | Familial Primary Pulmonary Hypertension | 12 | 2023 | 198 | 0.590 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 280 | 0.580 |
Why?
| | Oligonucleotide Array Sequence Analysis | 5 | 2010 | 761 | 0.560 |
Why?
| | Thrombosis | 4 | 2023 | 374 | 0.550 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2020 | 335 | 0.520 |
Why?
| | Growth Differentiation Factor 15 | 3 | 2013 | 40 | 0.510 |
Why?
| | Vascular Resistance | 5 | 2021 | 364 | 0.510 |
Why?
| | Exercise Test | 4 | 2024 | 622 | 0.490 |
Why?
| | Herpesviridae Infections | 3 | 2008 | 148 | 0.490 |
Why?
| | Hypoxia | 6 | 2024 | 1149 | 0.480 |
Why?
| | Endovascular Procedures | 1 | 2020 | 349 | 0.480 |
Why?
| | Patient Outcome Assessment | 1 | 2017 | 131 | 0.480 |
Why?
| | Altitude Sickness | 1 | 2017 | 148 | 0.460 |
Why?
| | Pulmonary Artery | 10 | 2023 | 1109 | 0.440 |
Why?
| | Vasodilator Agents | 4 | 2023 | 329 | 0.430 |
Why?
| | Echocardiography | 2 | 2020 | 640 | 0.420 |
Why?
| | Ventricular Function, Right | 5 | 2024 | 279 | 0.410 |
Why?
| | Humans | 69 | 2024 | 138651 | 0.410 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 857 | 0.400 |
Why?
| | Altitude | 1 | 2017 | 467 | 0.380 |
Why?
| | Endothelial Cells | 5 | 2011 | 791 | 0.370 |
Why?
| | Anticoagulants | 5 | 2023 | 667 | 0.370 |
Why?
| | Perioperative Care | 1 | 2014 | 213 | 0.360 |
Why?
| | Sulfones | 1 | 2012 | 110 | 0.360 |
Why?
| | Oxygen Consumption | 2 | 2024 | 710 | 0.340 |
Why?
| | Blood Cells | 1 | 2010 | 39 | 0.340 |
Why?
| | Herpesvirus 8, Human | 3 | 2008 | 66 | 0.320 |
Why?
| | Hypertension, Portal | 2 | 2020 | 64 | 0.320 |
Why?
| | Piperazines | 1 | 2012 | 345 | 0.310 |
Why?
| | Venous Thromboembolism | 3 | 2021 | 324 | 0.310 |
Why?
| | End Stage Liver Disease | 2 | 2020 | 69 | 0.310 |
Why?
| | Blood Coagulation | 3 | 2021 | 262 | 0.310 |
Why?
| | Neovascularization, Pathologic | 1 | 2011 | 296 | 0.300 |
Why?
| | Virus Diseases | 1 | 2011 | 214 | 0.290 |
Why?
| | Lung | 8 | 2022 | 4106 | 0.260 |
Why?
| | Walk Test | 2 | 2024 | 80 | 0.260 |
Why?
| | Acute Lung Injury | 1 | 2010 | 299 | 0.260 |
Why?
| | Time Factors | 2 | 2017 | 6851 | 0.260 |
Why?
| | Blood Vessels | 1 | 2008 | 180 | 0.260 |
Why?
| | Heart Ventricles | 5 | 2024 | 746 | 0.250 |
Why?
| | Middle Aged | 20 | 2024 | 33604 | 0.240 |
Why?
| | Male | 28 | 2024 | 68260 | 0.240 |
Why?
| | Mixed Connective Tissue Disease | 1 | 2005 | 9 | 0.240 |
Why?
| | Microarray Analysis | 1 | 2005 | 116 | 0.240 |
Why?
| | Respiratory Function Tests | 1 | 2007 | 561 | 0.240 |
Why?
| | Muscle, Smooth, Vascular | 3 | 2007 | 450 | 0.230 |
Why?
| | Cardiac Catheterization | 5 | 2023 | 529 | 0.220 |
Why?
| | Female | 27 | 2024 | 73763 | 0.220 |
Why?
| | Aromatase Inhibitors | 1 | 2024 | 58 | 0.220 |
Why?
| | Pulmonary Emphysema | 2 | 2007 | 311 | 0.210 |
Why?
| | Castleman Disease | 1 | 2003 | 13 | 0.210 |
Why?
| | Exercise | 4 | 2024 | 2072 | 0.190 |
Why?
| | Gene Expression Profiling | 2 | 2007 | 1746 | 0.190 |
Why?
| | Biopsy | 1 | 2005 | 1072 | 0.190 |
Why?
| | Heparin | 2 | 2021 | 258 | 0.190 |
Why?
| | Vascular Neoplasms | 1 | 2022 | 17 | 0.180 |
Why?
| | Cross-Over Studies | 1 | 2024 | 556 | 0.180 |
Why?
| | Endothelium, Vascular | 6 | 2007 | 935 | 0.180 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2021 | 24 | 0.180 |
Why?
| | Embolectomy | 1 | 2020 | 13 | 0.170 |
Why?
| | Aromatase | 1 | 2020 | 32 | 0.170 |
Why?
| | Growth Differentiation Factor 2 | 1 | 2020 | 2 | 0.170 |
Why?
| | Forced Expiratory Volume | 1 | 2021 | 488 | 0.160 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2020 | 24 | 0.160 |
Why?
| | Pulmonary Circulation | 4 | 2023 | 438 | 0.160 |
Why?
| | Thrombectomy | 1 | 2020 | 73 | 0.160 |
Why?
| | Tuberculosis | 1 | 2003 | 280 | 0.160 |
Why?
| | Drug Resistance | 1 | 2020 | 149 | 0.160 |
Why?
| | Tissue Plasminogen Activator | 1 | 2021 | 229 | 0.160 |
Why?
| | Aged | 12 | 2024 | 24024 | 0.160 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2020 | 139 | 0.160 |
Why?
| | Vascular Stiffness | 1 | 2023 | 443 | 0.150 |
Why?
| | Risk Factors | 7 | 2018 | 10252 | 0.140 |
Why?
| | Sildenafil Citrate | 2 | 2023 | 59 | 0.140 |
Why?
| | Polymerase Chain Reaction | 3 | 2008 | 1047 | 0.140 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 326 | 0.140 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2018 | 67 | 0.140 |
Why?
| | Estrogens | 1 | 2020 | 365 | 0.140 |
Why?
| | Acute Disease | 1 | 2020 | 994 | 0.130 |
Why?
| | Critical Illness | 2 | 2021 | 831 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 272 | 0.130 |
Why?
| | Thrombospondin 1 | 1 | 2017 | 28 | 0.130 |
Why?
| | Hemodynamics | 2 | 2014 | 1093 | 0.130 |
Why?
| | Schistosoma | 1 | 2017 | 28 | 0.130 |
Why?
| | Purines | 2 | 2023 | 179 | 0.130 |
Why?
| | Natriuretic Peptide, Brain | 2 | 2021 | 98 | 0.130 |
Why?
| | Transforming Growth Factor beta | 2 | 2017 | 488 | 0.130 |
Why?
| | Risk Assessment | 3 | 2023 | 3433 | 0.130 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2016 | 39 | 0.120 |
Why?
| | Adult | 15 | 2024 | 38201 | 0.120 |
Why?
| | Bone Marrow Cells | 1 | 2017 | 325 | 0.120 |
Why?
| | Pandemics | 2 | 2021 | 1641 | 0.120 |
Why?
| | Systole | 1 | 2016 | 174 | 0.120 |
Why?
| | Treatment Outcome | 8 | 2024 | 10923 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2013 | 1034 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 370 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 367 | 0.110 |
Why?
| | Patient Care Team | 1 | 2020 | 647 | 0.110 |
Why?
| | Cohort Studies | 3 | 2017 | 5697 | 0.110 |
Why?
| | Health Surveys | 1 | 2017 | 504 | 0.110 |
Why?
| | Retrospective Studies | 8 | 2023 | 15909 | 0.110 |
Why?
| | Myocardial Contraction | 1 | 2016 | 303 | 0.110 |
Why?
| | Prognosis | 3 | 2013 | 3984 | 0.110 |
Why?
| | Intensive Care Units | 1 | 2020 | 853 | 0.110 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2011 | 91 | 0.110 |
Why?
| | Blood Pressure | 2 | 2016 | 1739 | 0.110 |
Why?
| | Heart Failure | 2 | 2020 | 2067 | 0.110 |
Why?
| | ROC Curve | 1 | 2016 | 562 | 0.110 |
Why?
| | Heart-Assist Devices | 1 | 2020 | 557 | 0.100 |
Why?
| | Positive-Pressure Respiration | 1 | 2014 | 104 | 0.100 |
Why?
| | Precision Medicine | 1 | 2017 | 424 | 0.100 |
Why?
| | Anesthetics | 1 | 2014 | 98 | 0.100 |
Why?
| | Lung Diseases, Interstitial | 2 | 2013 | 651 | 0.100 |
Why?
| | Respiratory System Agents | 1 | 2013 | 23 | 0.100 |
Why?
| | Drug Discovery | 1 | 2013 | 144 | 0.100 |
Why?
| | Leukocytes, Mononuclear | 2 | 2007 | 571 | 0.100 |
Why?
| | Follow-Up Studies | 3 | 2021 | 5112 | 0.100 |
Why?
| | Drug Storage | 1 | 2012 | 53 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1567 | 0.090 |
Why?
| | Drug Stability | 1 | 2012 | 164 | 0.090 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2011 | 23 | 0.090 |
Why?
| | Phenotype | 3 | 2010 | 3139 | 0.090 |
Why?
| | Drug Approval | 1 | 2012 | 91 | 0.090 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 2011 | 11 | 0.090 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2011 | 36 | 0.090 |
Why?
| | Troponin | 1 | 2011 | 51 | 0.090 |
Why?
| | Blood Gas Analysis | 1 | 2011 | 83 | 0.090 |
Why?
| | Reproducibility of Results | 2 | 2010 | 3307 | 0.090 |
Why?
| | Europe | 1 | 2012 | 407 | 0.090 |
Why?
| | Hyponatremia | 1 | 2011 | 43 | 0.090 |
Why?
| | Case-Control Studies | 4 | 2020 | 3523 | 0.090 |
Why?
| | Medical History Taking | 1 | 2011 | 116 | 0.090 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 80 | 0.090 |
Why?
| | Antithrombins | 1 | 2011 | 62 | 0.090 |
Why?
| | Receptors, Interleukin-7 | 1 | 2010 | 27 | 0.080 |
Why?
| | Double-Blind Method | 3 | 2024 | 1949 | 0.080 |
Why?
| | Ultrasonography | 2 | 2011 | 745 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 4 | 2023 | 3637 | 0.080 |
Why?
| | Predictive Value of Tests | 4 | 2023 | 2030 | 0.080 |
Why?
| | Registries | 3 | 2022 | 2073 | 0.080 |
Why?
| | Mutation, Missense | 1 | 2011 | 334 | 0.080 |
Why?
| | Demography | 1 | 2010 | 296 | 0.080 |
Why?
| | Aldosterone | 1 | 2009 | 42 | 0.080 |
Why?
| | Drug Delivery Systems | 1 | 2012 | 359 | 0.070 |
Why?
| | Cluster Analysis | 1 | 2010 | 517 | 0.070 |
Why?
| | Vasopressins | 1 | 2009 | 60 | 0.070 |
Why?
| | Caspase 7 | 1 | 2008 | 22 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2022 | 2527 | 0.070 |
Why?
| | Vasoconstrictor Agents | 1 | 2009 | 133 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 984 | 0.070 |
Why?
| | In Situ Nick-End Labeling | 1 | 2008 | 126 | 0.070 |
Why?
| | Bone Morphogenetic Protein 4 | 1 | 2008 | 43 | 0.070 |
Why?
| | Electrocardiography | 1 | 2011 | 612 | 0.070 |
Why?
| | Prospective Studies | 4 | 2022 | 7554 | 0.070 |
Why?
| | Culture Media, Conditioned | 1 | 2008 | 112 | 0.070 |
Why?
| | Intramolecular Oxidoreductases | 2 | 2005 | 68 | 0.070 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 2005 | 158 | 0.070 |
Why?
| | Fluorescent Antibody Technique | 1 | 2008 | 385 | 0.070 |
Why?
| | Caspase 3 | 1 | 2008 | 249 | 0.070 |
Why?
| | Research Design | 1 | 2013 | 1118 | 0.070 |
Why?
| | Animals | 10 | 2017 | 37217 | 0.070 |
Why?
| | United States | 4 | 2022 | 14938 | 0.070 |
Why?
| | Acrolein | 1 | 2007 | 23 | 0.070 |
Why?
| | Survival Analysis | 1 | 2010 | 1309 | 0.060 |
Why?
| | Multivariate Analysis | 1 | 2010 | 1482 | 0.060 |
Why?
| | Colorado | 1 | 2017 | 4555 | 0.060 |
Why?
| | Flow Cytometry | 1 | 2010 | 1192 | 0.060 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2007 | 145 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 849 | 0.060 |
Why?
| | Endothelin A Receptor Antagonists | 1 | 2005 | 26 | 0.060 |
Why?
| | Pleural Diseases | 1 | 2005 | 23 | 0.060 |
Why?
| | Quality of Life | 3 | 2022 | 2954 | 0.060 |
Why?
| | Endothelial Growth Factors | 2 | 2002 | 65 | 0.060 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2005 | 76 | 0.060 |
Why?
| | Comorbidity | 1 | 2010 | 1656 | 0.060 |
Why?
| | Lymphokines | 2 | 2002 | 133 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2011 | 4181 | 0.050 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2010 | 1098 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2008 | 737 | 0.050 |
Why?
| | Cattle | 2 | 2017 | 991 | 0.050 |
Why?
| | Apoptosis | 3 | 2008 | 2546 | 0.050 |
Why?
| | Interleukin-6 | 1 | 2008 | 785 | 0.050 |
Why?
| | Vasodilation | 3 | 2010 | 509 | 0.050 |
Why?
| | Blood Circulation | 1 | 2003 | 44 | 0.050 |
Why?
| | CD36 Antigens | 1 | 2003 | 36 | 0.050 |
Why?
| | E-Selectin | 1 | 2003 | 56 | 0.050 |
Why?
| | Algorithms | 1 | 2011 | 1740 | 0.050 |
Why?
| | Nitriles | 1 | 2024 | 176 | 0.050 |
Why?
| | Forecasting | 1 | 2005 | 382 | 0.050 |
Why?
| | Veins | 1 | 2003 | 66 | 0.050 |
Why?
| | Biomarkers | 4 | 2013 | 4092 | 0.050 |
Why?
| | Blood | 1 | 2003 | 113 | 0.050 |
Why?
| | Adolescent | 4 | 2021 | 21564 | 0.050 |
Why?
| | Blood Donors | 1 | 2004 | 110 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2005 | 666 | 0.050 |
Why?
| | Administration, Inhalation | 1 | 2024 | 595 | 0.050 |
Why?
| | Postmenopause | 1 | 2024 | 370 | 0.050 |
Why?
| | Pulmonary Alveoli | 1 | 2005 | 408 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2005 | 1032 | 0.050 |
Why?
| | Receptors, Growth Factor | 1 | 2002 | 56 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2003 | 327 | 0.050 |
Why?
| | Drainage | 1 | 2003 | 173 | 0.050 |
Why?
| | Vascular Diseases | 1 | 2005 | 240 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2016 | 4315 | 0.050 |
Why?
| | Partial Thromboplastin Time | 1 | 2021 | 53 | 0.040 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2023 | 209 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2005 | 1233 | 0.040 |
Why?
| | Vascular Remodeling | 1 | 2023 | 192 | 0.040 |
Why?
| | Cytochrome P-450 CYP1B1 | 1 | 2020 | 5 | 0.040 |
Why?
| | Rivaroxaban | 1 | 2023 | 256 | 0.040 |
Why?
| | Catheters | 1 | 2021 | 74 | 0.040 |
Why?
| | Brachial Artery | 2 | 1999 | 202 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2003 | 492 | 0.040 |
Why?
| | Proteomics | 2 | 2022 | 1110 | 0.040 |
Why?
| | Liver Function Tests | 1 | 2020 | 104 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5520 | 0.040 |
Why?
| | Blood Coagulation Tests | 1 | 2020 | 68 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2002 | 231 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 319 | 0.040 |
Why?
| | Outpatients | 1 | 2023 | 419 | 0.040 |
Why?
| | Estrogen Receptor alpha | 1 | 2020 | 143 | 0.040 |
Why?
| | Smoking | 1 | 2007 | 1591 | 0.040 |
Why?
| | Mass Screening | 1 | 2007 | 1292 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1731 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2590 | 0.040 |
Why?
| | Drug Monitoring | 1 | 2020 | 215 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2022 | 1229 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2022 | 258 | 0.040 |
Why?
| | Enalapril | 1 | 1998 | 16 | 0.040 |
Why?
| | Hemorrhage | 1 | 2023 | 747 | 0.040 |
Why?
| | Survival Rate | 1 | 2022 | 1935 | 0.030 |
Why?
| | Antigens, Ly | 1 | 2017 | 43 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 368 | 0.030 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 99 | 0.030 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 1998 | 196 | 0.030 |
Why?
| | Peptide Fragments | 1 | 2021 | 693 | 0.030 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 2 | 2010 | 52 | 0.030 |
Why?
| | Education | 1 | 2017 | 108 | 0.030 |
Why?
| | Th2 Cells | 1 | 2017 | 177 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 858 | 0.030 |
Why?
| | Signal Transduction | 2 | 2020 | 5086 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2023 | 2480 | 0.030 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 245 | 0.030 |
Why?
| | Monocytes | 1 | 2017 | 573 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2016 | 487 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2016 | 859 | 0.030 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2013 | 8 | 0.030 |
Why?
| | Liver Transplantation | 1 | 2020 | 749 | 0.030 |
Why?
| | Hospitalization | 1 | 2023 | 2235 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2113 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 817 | 0.020 |
Why?
| | Mice | 2 | 2007 | 17814 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2003 | 2698 | 0.020 |
Why?
| | Perioperative Period | 1 | 2012 | 64 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2013 | 137 | 0.020 |
Why?
| | Sp1 Transcription Factor | 1 | 2011 | 25 | 0.020 |
Why?
| | Cell Growth Processes | 1 | 2011 | 53 | 0.020 |
Why?
| | International Cooperation | 1 | 2012 | 202 | 0.020 |
Why?
| | Vascular Endothelial Growth Factors | 2 | 2002 | 80 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 2011 | 116 | 0.020 |
Why?
| | Nitric Oxide | 2 | 2010 | 893 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2011 | 238 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2018 | 7677 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2850 | 0.020 |
Why?
| | Radiography, Thoracic | 1 | 2011 | 172 | 0.020 |
Why?
| | Introns | 1 | 2011 | 254 | 0.020 |
Why?
| | Physical Examination | 1 | 2012 | 238 | 0.020 |
Why?
| | RNA Splicing | 1 | 2011 | 270 | 0.020 |
Why?
| | Radiation Dosage | 1 | 2011 | 188 | 0.020 |
Why?
| | Leg | 1 | 2011 | 233 | 0.020 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2011 | 259 | 0.020 |
Why?
| | Lung Transplantation | 1 | 2013 | 314 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2017 | 2815 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2002 | 549 | 0.020 |
Why?
| | Anesthesia | 1 | 2012 | 245 | 0.020 |
Why?
| | Spironolactone | 1 | 2009 | 34 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 623 | 0.020 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2009 | 55 | 0.020 |
Why?
| | Contrast Media | 1 | 2011 | 463 | 0.020 |
Why?
| | Binding Sites | 1 | 2011 | 1313 | 0.020 |
Why?
| | Mutation | 3 | 2005 | 3987 | 0.020 |
Why?
| | Endothelin-1 | 1 | 2010 | 177 | 0.020 |
Why?
| | Health Status Indicators | 1 | 2009 | 163 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 5798 | 0.020 |
Why?
| | Research | 1 | 2009 | 451 | 0.010 |
Why?
| | Protein Binding | 1 | 2011 | 2225 | 0.010 |
Why?
| | Young Adult | 1 | 2021 | 13305 | 0.010 |
Why?
| | Gene Expression | 1 | 2010 | 1488 | 0.010 |
Why?
| | Cell Culture Techniques | 1 | 2007 | 364 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2011 | 1471 | 0.010 |
Why?
| | Cell Count | 1 | 2005 | 325 | 0.010 |
Why?
| | Genes, Viral | 1 | 2003 | 92 | 0.010 |
Why?
| | Transcription Factors | 1 | 2011 | 1697 | 0.010 |
Why?
| | Pilot Projects | 1 | 2009 | 1765 | 0.010 |
Why?
| | Cyclins | 1 | 2003 | 92 | 0.010 |
Why?
| | Disease Progression | 1 | 2010 | 2749 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 108 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 2172 | 0.010 |
Why?
| | Hematopoietic Stem Cells | 1 | 2005 | 410 | 0.010 |
Why?
| | DNA, Viral | 1 | 2003 | 365 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1998 | 3706 | 0.010 |
Why?
| | Viral Proteins | 1 | 2003 | 362 | 0.010 |
Why?
| | Microsatellite Repeats | 1 | 2001 | 159 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2012 | 2722 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2003 | 819 | 0.010 |
Why?
| | Vasoconstriction | 1 | 2001 | 219 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2001 | 395 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2012 | 5803 | 0.010 |
Why?
| | Ovarian Neoplasms | 1 | 2005 | 562 | 0.010 |
Why?
| | Ultrasonography, Doppler, Pulsed | 1 | 1999 | 7 | 0.010 |
Why?
| | Administration, Sublingual | 1 | 1999 | 12 | 0.010 |
Why?
| | Nitroglycerin | 1 | 1999 | 14 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 6829 | 0.010 |
Why?
| | Lipoprotein(a) | 1 | 1999 | 66 | 0.010 |
Why?
| | Cholesterol, HDL | 1 | 1999 | 195 | 0.010 |
Why?
| | Video Recording | 1 | 1999 | 181 | 0.010 |
Why?
| | Arteriosclerosis | 1 | 1998 | 83 | 0.010 |
Why?
| | Fibrinogen | 1 | 1999 | 173 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 1999 | 411 | 0.010 |
Why?
| | Reference Values | 1 | 1999 | 799 | 0.010 |
Why?
| | Diabetic Angiopathies | 1 | 1998 | 250 | 0.010 |
Why?
| | Regression Analysis | 1 | 1998 | 1017 | 0.010 |
Why?
| | Military Personnel | 1 | 1999 | 609 | 0.010 |
Why?
|
|
Bull's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|